Literature DB >> 11738469

Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease.

Steven M Singer1, Gina M Zainelli, Maryam A Norlund, John M Lee, Nancy A Muma.   

Abstract

Transglutaminase-catalyzed epsilon(gamma-glutamyl)lysine cross-links exist in Alzheimer's disease (AD) paired helical filament (PHF) tau protein but not normal soluble tau. To test the hypothesis that these cross-links could play a role in the formation of neurofibrillary tangles (NFT), we used single- and double-label immunofluorescence confocal microscopy and immunoaffinity purification and immunoblotting to examine epsilon(gamma-glutamyl)lysine cross-links in AD and control brains. The number of neurons that are immunoreactive with an antibody directed at the epsilon-(gamma-glutamyl)lysine bond was significantly higher in AD cortex compared with age-matched controls and schizophrenics. PHF tau-directed antibodies AT8, MC-1 and PHF-1 co-localized with epsilon(gamma-glutamyl)lysine immunolabeling in AD NFT. Immunoaffinity purification and immunoblotting experiments demonstrated that PHF tau contains epsilon(gamma-glutamyl)lysine bonds in parietal and frontal cortex in AD. In control cases with NFT present in the entorhinal cortex and hippocampus, indicative of Braak and Braak stage II, epsilon(gamma-glutamyl)lysine bonds were present in PHF tau in parietal and frontal cortex, despite the lack of microscopically detectable NFT or senile plaques in these cortical regions. The presence of PHF tau with epsilon(gamma-glutamyl)lysine bonds in brain regions devoid of NFT in stage II (but regions, which would be expected to contain NFT in stage III) suggests that these bonds occur early in the formation of NFT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11738469     DOI: 10.1016/s0197-0186(01)00061-4

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  17 in total

1.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 2.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

3.  Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies.

Authors:  Micha M M Wilhelmus; Mieke de Jager; Annemieke J M Rozemuller; John Brevé; John G J M Bol; Richard L Eckert; Benjamin Drukarch
Journal:  J Pathol       Date:  2011-10-18       Impact factor: 7.996

Review 4.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

5.  Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain.

Authors:  Soo-Youl Kim; Lyuben Marekov; Parvesh Bubber; Susan E Browne; Irina Stavrovskaya; Jongmin Lee; Peter M Steinert; John P Blass; M Flint Beal; Gary E Gibson; Arthur J L Cooper
Journal:  Neurochem Res       Date:  2005-10       Impact factor: 3.996

6.  Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria.

Authors:  Boris F Krasnikov; Soo-Youl Kim; Stephen J McConoughey; Hoon Ryu; Hui Xu; Irina Stavrovskaya; Siiri E Iismaa; Bryony M Mearns; Rajiv R Ratan; John P Blass; Gary E Gibson; Arthur J L Cooper
Journal:  Biochemistry       Date:  2005-05-31       Impact factor: 3.162

7.  Tissue Transglutaminase and Its Product Isopeptide Are Increased in Alzheimer's Disease and APPswe/PS1dE9 Double Transgenic Mice Brains.

Authors:  Ji Zhang; Suqing Wang; Wei Huang; David A Bennett; Dennis W Dickson; Dengshun Wang; Rui Wang
Journal:  Mol Neurobiol       Date:  2015-09-19       Impact factor: 5.590

8.  Inhibition of tissue transglutaminase promotes Aβ-induced apoptosis in SH-SY5Y cells.

Authors:  Ji Zhang; Yi-Rong Ding; Rui Wang
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

9.  Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.

Authors:  Eunsung Junn; Ruben D Ronchetti; Martha M Quezado; Soo-Youl Kim; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

10.  Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views.

Authors:  Deng-Shun Wang; Dennis W Dickson; James S Malter
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.